In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Translate Bio Inc (TBIO), with a price target of $21. The company’s shares closed yesterday at $13.12.
Fein wrote:
“Valuation and risks to achievement of target price. Our price target of $21/share is based on an equally-weighted composite of: (a) $13.9/share, as a 35x multiple of taxed and diluted $4.25 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $27.4/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 10.2% and a 49.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Translate Bio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $21.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.60 and a one-year low of $4.81. Currently, Translate Bio Inc has an average volume of 193K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency.
